other material
confidence high
sentiment neutral
materiality 0.75
Viridian Therapeutics raises ~$258.8M in public offering of common and Series B preferred stock
Viridian Therapeutics, Inc.\DE
- 10,666,600 common shares at $18.75/share and 20,000 Series B non-voting convertible preferred shares at $1,250.06250/share offered.
- Underwriters' option for 1,800,000 additional common shares exercised in full on September 12, 2024.
- Aggregate gross proceeds approximately $258.8 million before underwriting discounts and expenses.
- Net proceeds expected to fund operations into the second half of 2027.
- Closing of the offering expected on September 13, 2024 under existing shelf registration statement.